-
1.发明授权公开(公告)号：US11957762B2
公开(公告)日：2024-04-16
申请号：US15577998
申请日：2016-05-27
Applicant: University of Utah Research Foundation
Inventor： Mingnan Chen , Hyung Jin Cho , Peng Wang , Shuyun Dong , Peng Zhao
IPC: A61K47/64 , A61K31/337 , A61K31/35 , A61K38/00 , A61K39/00 , A61P35/00 , A61P35/04 , C07K14/77 , C07K14/78
CPC classification number: A61K47/6435 , A61K31/337 , A61K31/35 , A61K39/0005 , A61K47/64 , A61P35/00 , A61P35/04 , C07K14/77 , C07K14/78 , A61K38/00 , A61K2039/6031 , C07K2319/00
Abstract: Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats; and, non-immunogenic bioconjugates comprising recombinant polypeptides comprising one or more homologous amino acid repeats and one or more therapeutic agents. Also, disclosed herein are pharmaceutical compositions including the recombinant polypeptides; and methods of administering the recombinant polypeptides to patients for the treatment of cancer or infections.
-
2.发明公开公开(公告)号：US20230322884A1
公开(公告)日：2023-10-12
申请号：US18118971
申请日：2023-03-08
Applicant: Selecta Biosciences, Inc.
Inventor： Takashi Kei Kishimoto , Petr Ilyinskii
CPC classification number: C07K14/55 , C12N15/86 , C12N2750/14143 , A61P37/02 , C07K14/77
Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for modulating an immune response to an antigen, such as by enhancing regulatory T cells, such as antigen-specific regulatory T cells.
-
公开(公告)号：US20230257793A1
公开(公告)日：2023-08-17
申请号：US18024706
申请日：2021-09-05
Applicant: Ginkgo Bioworks, Inc.
Inventor： Nikos Reppas , Swaminath Srinivas , Adam Meyer , Alex Tucker , Punita Manga , Sneha Srikrishnan
CPC classification number: C12P21/02 , C12N15/635 , C12N15/815 , C12N9/2414 , C12N9/1029 , C12Y203/01037 , C12N15/52 , C07K14/795 , C07K14/77 , C12N2830/001 , C12N2800/102
Abstract: This application describes transcriptional units, synthetic expression systems, and host cells comprising transcriptional units and synthetic expression systems, wherein the synthetic expression system is capable of expressing a gene of interest. Also described are methods for the production of bioproducts (including, but not limited to, proteins or RNA expressed from the gene of interest). In some embodiments, bioproducts are produced from host cells under culture conditions without addition of methanol.
-
公开(公告)号：US20230086338A1
公开(公告)日：2023-03-23
申请号：US18057134
申请日：2022-11-18
Applicant: CLARA FOODS CO.
Inventor： Kritika MAHADEVAN , Ying Joy ZHONG , Isha JOSHI , Farnoosh AYOUGHI , Ranjan PATNAIK , A. Samuel POTTINGER , Dane Mathias JACOBSON , Andrew MIYASHIRO , Harshal KSHIRSAGAR
IPC: A23L15/00 , A23J1/18 , A23J1/14 , C07K14/465 , C07K14/77
Abstract: The present disclosure provides compositions for preparation of egg-like products.
-
公开(公告)号：US20220233607A1
公开(公告)日：2022-07-28
申请号：US17614771
申请日：2020-05-29
Applicant: UNIVERSITÉ DE TOURS , KYMERIS THERAPEUTICS INC. , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
Inventor： Isabelle DIMIER-POISSON , Marie-Noëlle MEVELEC , Anne DI TOMMASO , Nicolas AUBREY , Louis LANTIER , Gordon LEE
IPC: A61K35/68 , C07K14/54 , C07K14/715 , C07K14/77 , C07K16/28
Abstract: A strain of an Apicomplexa of the family Sarcocystidae, wherein the strain is replicative and expresses one or more heterologous protein(s) selected from the group including therapeutic proteins, antigens, recombinant surface receptor or combinations thereof, and wherein the strain is selected from the group including Toxoplasma gondii and Neospora caninium. Also, the use of the strain for preventing or treating cancers or infectious diseases in a subject in need thereof.
-
Patent Agency Ranking
公开(公告)号：US20210308260A1
公开(公告)日：2021-10-07
申请号：US17050666
申请日：2019-04-23
Inventor： Nan DAI , Yonggang ZHAO
IPC: A61K39/385 , C07K14/195 , C07K14/77 , C07K14/47 , A61K39/02 , A61K39/00 , A61K45/06 , A61P35/00
Abstract: Disclosed are a non-integrative Listeria-based vaccine and a method for inducing antitumor immune response. In particular, the present disclosure provides a recombinant nucleic acid molecule, a recombinant plasmid or a recombinant expression vector comprising the recombinant nucleic acid molecule, a recombinant protein, and a recombinant Listeria. Also disclosed are a pharmaceutical composition and a vaccine comprising the above component, a method for slowly and continuously killing cells using the same, and a method for inducing immune response in a subject using the same.
-
公开(公告)号：US20210238277A1
公开(公告)日：2021-08-05
申请号：US17143731
申请日：2021-01-07
Inventor： Jeffrey A. Hubbell , Stephan Kontos , Karen Y. Dane
IPC: C07K16/28 , A61K39/00 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K14/47 , A61K47/68 , C07K7/08 , C07K14/77
Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
-
公开(公告)号：US10919963B2
公开(公告)日：2021-02-16
申请号：US16523877
申请日：2019-07-26
Inventor： Jeffrey A. Hubbell , Stephan Kontos , Karen Y. Dane
IPC: C07K16/28 , A61K39/00 , B82Y5/00 , C07K16/18 , C07K16/30 , C07K14/47 , A61K47/68 , C07K7/08 , C07K14/77 , A61K38/00
Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
-
公开(公告)号：US20190106476A1
公开(公告)日：2019-04-11
申请号：US16089335
申请日：2017-05-17
Applicant: Cue Biopharma, Inc.
Inventor： Ronald D. Seidel, III , Rodolfo Chaparro
IPC: C07K14/705 , C07K14/74 , C07K14/77 , C07K14/715 , A61P35/00
Abstract: The present disclosure provides T-cell modulatory multimeric polypeptides comprising two different immunomodulatory polypeptides, at least one of which is a variant immunomodulatory polypeptide. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
-
公开(公告)号：US09862772B2
公开(公告)日：2018-01-09
申请号：US14426650
申请日：2013-09-06
Inventor： Andreas Radbruch , Falk Hiepe , Adriano Taddeo , Velia Gerl , Bimba F. Hoyer , Hyun-Dong Chang , Andreas Theiel
IPC: A61K39/395 , C07K16/28 , C07K14/77 , C07K14/47 , A61K39/00 , G01N33/569
CPC classification number: C07K16/2896 , A61K39/0008 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K14/4713 , C07K14/77 , C07K16/2884 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/33 , C07K2319/70 , C07K2319/74 , G01N33/56972 , G01N2800/24
Abstract: The invention relates to a composition comprising an anchor region capable of binding to a plasma cell; and a binding region associated with the anchor region, wherein the binding region binds a specific plasma cell antibody.
-
-
-
-
-
-
-
-
-
Search Results
184
records
(took 0.027 seconds)
